On February 12, 2015, Guangdong Taienkang Pharmaceutical Co., Ltd. (hereinafter referred to as "Taienkang") completed the acquisition of 100% equity of Ma’anshan Tianfukang Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianfukang"), and Tianfukang became Taienkang’s sixth wholly-owned subsidiary.

Tianfukang is an enterprise mainly producing traditional Chinese medicine preparations, mainly producing pills (concentrated pills, honeyed pills, honeyed water pills, watered pills), tablets, hard capsules, and granules. Extract production. As a leading enterprise of agricultural industrialization in Ma’anshan City, a private technology enterprise and a high-tech enterprise in Anhui Province, Tianfukang has excellent production technology and a high-quality production and R&D technical team. "Tianfukang" brand Compound Black Chicken Pills and Pills of Six Drugs Including Rehmannia and other series Pills are very popular in the market.

This acquisition fills in the blank of Taienkang in the field of Chinese herbal decoction pieces, pretreatment of traditional Chinese medicine, and oral preparations, realizes the business extension of Taienkang in pharmaceutical production, expands the scope of business, further improves the product chain, and is conducive to improving The company’s business income has formed a new profit growth point.

After the acquisition and business adjustment are completed, the company will greatly increase the capital investment in Tianfukang, unite with well-known domestic research institutes, improve the research and development space, introduce domestic cutting-edge drugs, improve pharmaceutical technology, and combine the company’s good professional management team and perfect sales network and brand effect, through resource integration, introduce modern management methods and business models, enhance Tianfukang’s sustainable development ability and comprehensive competitiveness, so as to develop the company’s R&D and pharmaceutical capabilities faster, and expand the company’s industrial structure of research, production and sales. Improve the return on assets and maximize the value of the company’s shareholders.